PROTACs, molecular glues and other degraders

8-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetyl]piperazin-1-yl]-9-ethyl-6,6-dimethyl-11-oxo-5H-benzo[b]carbazole-3-carbonitrile.

A947.

A947.

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib ( HY-16297A ), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib ( HY-16297A ), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib ( HY-16297A ), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib ( HY-16297A ), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib ( HY-16297A ), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib ( HY-16297A ), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6

Abemaciclib metabolite M18-d 8 is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib ( HY-16297A ), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a

AK-2292.

AK-2292.